Arbutus Biopharma - ABUS Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABUS shares.
View ABUS analyst ratings or view top-rated stocks.

4 brokerages have issued 1 year price targets for Arbutus Biopharma's shares. Their ABUS share price forecasts range from $5.00 to $9.00. On average, they expect the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 121.8% from the stock's current price.
View analysts price targets for ABUS or view top-rated stocks among Wall Street analysts.

Arbutus Biopharma's stock was trading at $2.33 at the start of the year. Since then, ABUS stock has increased by 25.8% and is now trading at $2.93.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our ABUS earnings forecast.

Arbutus Biopharma Co. (NASDAQ:ABUS) posted its quarterly earnings data on Wednesday, November, 9th. The biopharmaceutical company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). The biopharmaceutical company had revenue of $5.95 million for the quarter, compared to analyst estimates of $11.12 million. Arbutus Biopharma had a negative net margin of 191.34% and a negative trailing twelve-month return on equity of 43.44%.

6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Arbutus Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.55%) and Clear Harbor Asset Management LLC (0.04%).
View institutional ownership trends.

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABUS stock can currently be purchased for approximately $2.93.

Arbutus Biopharma (NASDAQ:ABUS) has a market capitalization of $439.36 million and generates $10.99 million in revenue each year. The biopharmaceutical company earns $-76,250,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The official website for the company is www.arbutusbio.com. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at ir@arbutusbio.com, or via fax at 604-419-3201.